Locus Cell Co

Locus Cell Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Locus Cell Co (6891.TWO) as of Oct 17, 2026 is 1.94. In the previous year, Net Debt to Free Cash Flow Ratio was 10.07 — a change of -80.71% (lower).

Net Debt/FCF

1.94

YoY

-80.71%

Last updated:

Net Debt to Free Cash Flow Ratio of Locus Cell Co is 2024 1.94 . Net Debt to Free Cash Flow Ratio of Locus Cell Co was 2023 10.07 . It decreases by -80.71% lower compared to the previous year.

The Locus Cell Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2021
62.20 TWD
Jan 1, 2022
29.01 TWD
Jan 1, 2023
10.07 TWD
Jan 1, 2024
1.94 TWD
The Locus Cell Co Net Debt/FCF history
YEARNet Debt/FCFYoY
1.94-80.71%
10.07-65.30%
29.01-53.37%
62.20—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Locus Cell Co Stock analysis

What does Locus Cell Co do? Locus Cell Co Ltd is a company based in Taipei, Taiwan, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company has 32 employees and went public on April 28, 2022. Its primary business involves the entrusted development and manufacturing of cell therapy-related products. Locus Cell Co Ltd utilizes a pilot facility compliant with Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP). The company provides services including process development and scale-up for cell therapy products, analytical method development and validation, clinical GMP manufacturing for trials, and stability testing. It is anticipated to offer services for various cell therapy applications, such as tissue engineering, CAR-T, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs). The company's website is http://www.locus-cell.com/. Locus Cell Co Ltd focuses on contract development and manufacturing organization (CDMO) services for cell therapy products, aiming to support the advancement of innovative therapies through its specialized GMP-compliant facility and technical expertise in cell therapy processes. Locus Cell Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Locus Cell Co stock

Net Debt to Free Cash Flow Ratio of Locus Cell Co is 1.94 in 2024.

Net Debt to Free Cash Flow Ratio of Locus Cell Co changed from 10.07 to 1.94, representing a -80.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Locus Cell Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Locus Cell Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Locus Cell Co

All Key Metrics — Locus Cell Co